Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

INDP Indaptus Therapeutics Inc

0,842

0,0019 (0,23%)

18 Jan 2025 - Geschlossen

Verzögert um 15 Minuten

Form D - Notice of Exempt Offering of Securities

Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
Von Dez 2024 bis Jan 2025

Click Here for more Indaptus Therapeutics Charts.

Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
Von Jan 2024 bis Jan 2025

Click Here for more Indaptus Therapeutics Charts.

News Indaptus Therapeutics Inc

Form 8-K - Current report
Dienstag 14 Januar 2025 (3 Tage vor) • Edgar (US Regulatory)

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Montag 13 Januar 2025 (5 Tage vor) • GlobeNewswire Inc.

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025
Mittwoch 8 Januar 2025 (1 Woche vor) • GlobeNewswire Inc.

Form EFFECT - Notice of Effectiveness
Donnerstag 2 Januar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933
Montag 23 Dezember 2024 (4 Wochen vor) • Edgar (US Regulatory)

Form 8-K - Current report
Freitag 22 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Freitag 22 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement
Freitag 22 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Form 8-K - Current report
Dienstag 12 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Dienstag 12 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Montag 11 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Donnerstag 7 November 2024 (2 Monate vor) • GlobeNewswire Inc.

Weitere Indaptus Therapeutics Inc News-Artikel

Check Point Software Tec...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen